xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06025357</url>
    </required_header>
    <id_info>
      <org_study_id>IRB2022-362</org_study_id>
      <nct_id>NCT06025357</nct_id>
    </id_info>
    <brief_title>Effects of L-citrulline Supplementation on Vascular Function in Metabolic Syndrome</brief_title>
    <official_title>Effects of L-Citrulline Supplementation on Vascular Function During Fasted and Acute Hyperglycemia in Middle-aged and Older Women With Metabolic Syndrome</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Texas Tech University</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Texas Tech University</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        The objective of this project is to provide evidence that L-Citrulline (CIT) supplementation&#xD;
        can improve vascular function in the fasted and acute hyperglycemia conditions in middle-aged&#xD;
        and older women with metabolic syndrome.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Using a double-blind, randomized, placebo-controlled, and parallel design, middle-aged and&#xD;
        older women with metabolic syndrome will be randomized into receiving either CIT&#xD;
        supplementation (10g/day) or placebo (Microcrystalline Cellulose) for 4 weeks.&#xD;
  &#xD;
        The first visit will be approximately 1hr and 30 minutes. The 2nd and 3rd visits will each be&#xD;
        approximately 2hrs and 30 minutes, separated by 4 weeks in between each visit. During visits&#xD;
        2 and 3, vascular measurements will be assessed in the fasted state and 30, 60, and 90&#xD;
        minutes after acute glucose ingestion (75g).&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Recruiting</overall_status>
    <start_date type="Actual">January 1, 2023</start_date>
    <completion_date type="Anticipated">August 1, 2024</completion_date>
    <primary_completion_date type="Anticipated">May 1, 2024</primary_completion_date>
    <phase>N/A</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <intervention_model_description>Parallel Assignment Double (Participant, Investigator) Randomized, double-blind, placebo-controlled, parallel study design</intervention_model_description>
      <primary_purpose>Basic Science</primary_purpose>
      <masking>Double (Participant, Investigator)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Macrovascular Endothelial function in the fasted condition</measure>
      <time_frame>4 weeks</time_frame>
      <description>Endothelial function will be measured via brachial artery flow mediated dilation (ultrasonography) during reactive hyperemia at baseline and after 4 weeks of supplementation.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Microvascular endothelial function in the fasted condition</measure>
      <time_frame>4 weeks</time_frame>
      <description>Endothelial function will be measured using forearm muscle oxygenation (near-infrared spectroscopy) will assessed during reactive hyperemia at baseline and after 4 weeks of supplementation.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Microvascular digital endothelial function in the fasted condition</measure>
      <time_frame>4 weeks</time_frame>
      <description>Endothelial function will be measured using peripheral (finger) arterial tonometry (EndoPAT device) during reactive hyperemia at baseline and after 4 weeks of supplementation.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Macrovascular Endothelial function during acute hyperglycemia</measure>
      <time_frame>4 weeks</time_frame>
      <description>Endothelial function will be measured via brachial artery flow mediated dilation (ultrasonography) during reactive hyperemia at 30, 60, and 90 minutes after oral glucose ingestion at baseline and after 4 weeks of supplementation.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Microvascular forearm endothelial function during acute hyperglycemia</measure>
      <time_frame>4 weeks</time_frame>
      <description>Endothelial function will be measured using forearm muscle oxygenation (near-infrared spectroscopy) during reactive hyperemia at 30, 60, and 90 minutes after oral glucose ingestion at baseline and after 4 weeks of supplementation.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Central and peripheral arterial stiffness in the fasted condition</measure>
      <time_frame>4 weeks</time_frame>
      <description>Arterial stiffness will be measured using central (carotid-femoral) and peripheral (femoral-ankle) PWV at baseline and after 4 weeks of supplementation.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Central arterial stiffness during acute hyperglycemia</measure>
      <time_frame>4 weeks</time_frame>
      <description>Arterial stiffness will be measured using central (carotid-femoral) PWV at 30, 60, and 90 minutes after oral glucose ingestion at baseline and after 4 weeks of supplementation.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Blood pressure in the fasted condition</measure>
      <time_frame>4 weeks</time_frame>
      <description>Brachial and aortic blood pressures will be assessed using an automated sphygmomanometry arm cuff (SphygmoCor XCEL). Beat-to-beat blood pressure will be measured using an automated photoplethysmography finger cuff (Fineometer). Blood pressure will be measured at baseline and after 4 weeks of supplementation.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Blood pressure during acute hyperglycemia</measure>
      <time_frame>4 weeks</time_frame>
      <description>Brachial and aortic blood pressures (systolic and diastolic) will be assessed using an automated sphygmomanometry arm cuff (SphygmoCor XCEL). Beat-to-beat blood pressure will be measured using an automated photoplethysmography finger cuff (Fineometer). Blood pressure will be measured after an oral glucose ingestion at 30, 60, and 90 minutes at baseline and after 4 weeks of supplementation.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Total peripheral resistance in the fasted condition.</measure>
      <time_frame>4 weeks</time_frame>
      <description>Total peripheral resistance will be measured using an automated photoplethysmography finger cuff (Finometer) at baseline and after 4 weeks of supplementation.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Total peripheral resistance during acute hyperglycemia</measure>
      <time_frame>4 weeks</time_frame>
      <description>Total peripheral resistance will be measured using an automated photoplethysmography finger cuff (Finometer) at 30, 60, and 90 minutes after oral glucose ingestion at baseline and after 4 weeks of supplementation.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Stroke volume in the fasted condition</measure>
      <time_frame>4 weeks</time_frame>
      <description>Stroke volume will be measured using an automated photoplethysmography finger cuff (Finometer) at baseline and after 4 weeks of supplementation.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Stroke volume during acute hyperglycemia</measure>
      <time_frame>4 weeks</time_frame>
      <description>Stroke volume will be measured using an automated photoplethysmography finger cuff (Finometer) at 30, 60, and 90 minutes after oral glucose ingestion at baseline and after 4 weeks of supplementation.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>24-hour ambulatory blood pressure monitoring</measure>
      <time_frame>4 weeks</time_frame>
      <description>An ambulatory blood pressure cuff, measuring blood pressure for 24-hours will be obtained on two separate days at baseline and after 4 weeks of supplementation.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Serum glucose and insulin levels.</measure>
      <time_frame>4 weeks</time_frame>
      <description>Serum glucose and insulin levels will be tested at baseline and after 4 weeks of supplementation.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Serum arginine levels</measure>
      <time_frame>4 weeks</time_frame>
      <description>Serum L-Arginine levels will be tested at baseline and after 4 weeks of supplementation.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Serum arginase levels</measure>
      <time_frame>4 weeks</time_frame>
      <description>Serum arginase levels will be tested at baseline and after 4 weeks of supplementation.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Serum Nitric Oxide levels</measure>
      <time_frame>4 weeks</time_frame>
      <description>Serum nitric oxide levels will be tested at baseline and after 4 weeks of supplementation.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Serum Endothelin-1 levels</measure>
      <time_frame>4 weeks</time_frame>
      <description>Serum endothelin-1 levels will be tested at baseline and after 4 weeks of supplementation.</description>
    </secondary_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Anticipated">24</enrollment>
    <condition>Metabolic Syndrome</condition>
    <condition>Menopause</condition>
    <arm_group>
      <arm_group_label>L-citrulline</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>L-citrulline: 10 grams/day</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Placebo</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Microcrystalline Cellulose</description>
    </arm_group>
    <intervention>
      <intervention_type>Dietary Supplement</intervention_type>
      <intervention_name>L-Citrulline supplementation</intervention_name>
      <description>4 weeks of L-Citrulline supplementation (10 grams/day).</description>
      <arm_group_label>L-citrulline</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Dietary Supplement</intervention_type>
      <intervention_name>Placebo</intervention_name>
      <description>4 weeks of microcrystalline Cellulose supplementation.</description>
      <arm_group_label>Placebo</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
          Must present at least 3 of the following 5 cardiometabolic risk factors&#xD;
  &#xD;
            -  Waist circumference ≥88 cm&#xD;
  &#xD;
            -  Fasting glucose between 100-125 mg/dL or HbA1c between 5.7-6.4%.&#xD;
  &#xD;
            -  Blood pressure ≥130 mm Hg&#xD;
  &#xD;
            -  Triglyceride ≥ 150 mg/dL&#xD;
  &#xD;
            -  HDL &lt;50 mg/dL&#xD;
  &#xD;
          The following are also inclusion criteria's:&#xD;
  &#xD;
            -  Women aged 45-79 years old&#xD;
  &#xD;
            -  Body mass index ≤ 39.9 kg/m2&#xD;
  &#xD;
            -  Sedentary (defined as &lt; 120 min/week of exercise)&#xD;
  &#xD;
            -  Abstain from any dietary supplements with vascular effects for one month prior to the&#xD;
               beginning of the study and until participation in study has terminated.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  &lt; 45 and &gt; 79 years of age&#xD;
  &#xD;
            -  Use of medications and/or any supplements that may affect outcome variables (such as&#xD;
               arginine-containing supplements, nitroglycerin, statin drugs, biguanides, insulin,&#xD;
               beta blockers, statins, verapamil)&#xD;
  &#xD;
            -  Systolic blood pressure ≥ 160 mmHg&#xD;
  &#xD;
            -  BMI &gt; 40 kg/m2&#xD;
  &#xD;
            -  Recent changes in medication (3 months)&#xD;
  &#xD;
            -  Current smoking any tobacco use&#xD;
  &#xD;
            -  Cardiovascular disease, diabetes (Type 1 or 2), and other metabolic or chronic&#xD;
               diseases&#xD;
  &#xD;
            -  More than 7 alcoholic drinks/week of consumption&#xD;
        </textblock>
      </criteria>
      <gender>Female</gender>
      <minimum_age>45 Years</minimum_age>
      <maximum_age>79 Years</maximum_age>
      <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Arturo Figueroa</last_name>
      <role>Principal Investigator</role>
      <affiliation>Texas Tech University</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Arturo Figueroa, Ph.D,MD</last_name>
      <phone>806-834-5587</phone>
      <email>arturo.figueroa@ttu.edu</email>
    </overall_contact>
    <location>
      <facility>
        <name>TTU Kinesiology and Sport Management Building</name>
        <address>
          <city>Lubbock</city>
          <state>Texas</state>
          <zip>79409</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Arturo Figueroa, M.D., Ph.D.</last_name>
        <phone>806-834-5587</phone>
      </contact>
    </location>
    <location_countries>
      <country>United States</country>
    </location_countries>
    <reference>
      <citation>Figueroa A, Maharaj A, Kang Y, Dillon KN, Martinez MA, Morita M, Nogimura D, Fischer SM. Combined Citrulline and Glutathione Supplementation Improves Endothelial Function and Blood Pressure Reactivity in Postmenopausal Women. Nutrients. 2023 Mar 23;15(7):1557. doi: 10.3390/nu15071557.</citation>
      <PMID>37049398</PMID>
    </reference>
    <reference>
      <citation>Maharaj A, Fischer SM, Dillon KN, Kang Y, Martinez MA, Figueroa A. Acute Citrulline Blunts Aortic Systolic Pressure during Exercise and Sympathoactivation in Hypertensive Postmenopausal Women. Med Sci Sports Exerc. 2022 May 1;54(5):761-768. doi: 10.1249/MSS.0000000000002848. Epub 2022 Jan 3.</citation>
      <PMID>34974502</PMID>
    </reference>
    <reference>
      <citation>McDonald JD, Mah E, Chitchumroonchokchai C, Dey P, Labyk AN, Villamena FA, Volek JS, Bruno RS. Dairy milk proteins attenuate hyperglycemia-induced impairments in vascular endothelial function in adults with prediabetes by limiting increases in glycemia and oxidative stress that reduce nitric oxide bioavailability. J Nutr Biochem. 2019 Jan;63:165-176. doi: 10.1016/j.jnutbio.2018.09.018. Epub 2018 Sep 25.</citation>
      <PMID>30412905</PMID>
    </reference>
    <reference>
      <citation>Figueroa A, Alvarez-Alvarado S, Ormsbee MJ, Madzima TA, Campbell JC, Wong A. Impact of L-citrulline supplementation and whole-body vibration training on arterial stiffness and leg muscle function in obese postmenopausal women with high blood pressure. Exp Gerontol. 2015 Mar;63:35-40. doi: 10.1016/j.exger.2015.01.046. Epub 2015 Jan 28.</citation>
      <PMID>25636814</PMID>
    </reference>
    <results_reference>
      <citation>Maharaj A, Fischer SM, Dillon KN, Kang Y, Martinez MA, Figueroa A. Effects of L-Citrulline Supplementation on Endothelial Function and Blood Pressure in Hypertensive Postmenopausal Women. Nutrients. 2022 Oct 20;14(20):4396. doi: 10.3390/nu14204396.</citation>
      <PMID>36297080</PMID>
    </results_reference>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>July 27, 2023</study_first_submitted>
    <study_first_submitted_qc>August 29, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">September 6, 2023</study_first_posted>
    <last_update_submitted>August 29, 2023</last_update_submitted>
    <last_update_submitted_qc>August 29, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 6, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>Texas Tech University</investigator_affiliation>
      <investigator_full_name>Arturo Figueroa</investigator_full_name>
      <investigator_title>Arturo Figueroa, Principal Investigator</investigator_title>
    </responsible_party>
    <keyword>Endothelial function</keyword>
    <keyword>Aortic Hemodynamics</keyword>
    <keyword>Blood pressure</keyword>
    <keyword>Obesity</keyword>
    <keyword>Hypertension</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Metabolic Syndrome</mesh_term>
      <mesh_term>Syndrome</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06025357
  org study id: IRB2022-362
  nct id: NCT06025357
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  The objective of this project is to provide evidence that L-Citrulline (CIT) supplementation
        can improve vascular function in the fasted and acute hyperglycemia conditions in middle-aged
        and older women with metabolic syndrome.
  Using a double-blind, randomized, placebo-controlled, and parallel design, middle-aged and
        older women with metabolic syndrome will be randomized into receiving either CIT
        supplementation (10g/day) or placebo (Microcrystalline Cellulose) for 4 weeks.
  
        The first visit will be approximately 1hr and 30 minutes. The 2nd and 3rd visits will each be
        approximately 2hrs and 30 minutes, separated by 4 weeks in between each visit. During visits
        2 and 3, vascular measurements will be assessed in the fasted state and 30, 60, and 90
        minutes after acute glucose ingestion (75g).
  allocation: Randomized
  intervention model: Parallel Assignment
  intervention model description: Parallel Assignment Double (Participant, Investigator) Randomized, double-blind, placebo-controlled, parallel study design
  primary purpose: Basic Science
  masking: Double (Participant, Investigator)
  measure: Macrovascular Endothelial function in the fasted condition
  time frame: 4 weeks
  description: Endothelial function will be measured via brachial artery flow mediated dilation (ultrasonography) during reactive hyperemia at baseline and after 4 weeks of supplementation.
  measure: Microvascular endothelial function in the fasted condition
  time frame: 4 weeks
  description: Endothelial function will be measured using forearm muscle oxygenation (near-infrared spectroscopy) will assessed during reactive hyperemia at baseline and after 4 weeks of supplementation.
  measure: Microvascular digital endothelial function in the fasted condition
  time frame: 4 weeks
  description: Endothelial function will be measured using peripheral (finger) arterial tonometry (EndoPAT device) during reactive hyperemia at baseline and after 4 weeks of supplementation.
  measure: Macrovascular Endothelial function during acute hyperglycemia
  time frame: 4 weeks
  description: Endothelial function will be measured via brachial artery flow mediated dilation (ultrasonography) during reactive hyperemia at 30, 60, and 90 minutes after oral glucose ingestion at baseline and after 4 weeks of supplementation.
  measure: Microvascular forearm endothelial function during acute hyperglycemia
  time frame: 4 weeks
  description: Endothelial function will be measured using forearm muscle oxygenation (near-infrared spectroscopy) during reactive hyperemia at 30, 60, and 90 minutes after oral glucose ingestion at baseline and after 4 weeks of supplementation.
  measure: Central and peripheral arterial stiffness in the fasted condition
  time frame: 4 weeks
  description: Arterial stiffness will be measured using central (carotid-femoral) and peripheral (femoral-ankle) PWV at baseline and after 4 weeks of supplementation.
  measure: Central arterial stiffness during acute hyperglycemia
  time frame: 4 weeks
  description: Arterial stiffness will be measured using central (carotid-femoral) PWV at 30, 60, and 90 minutes after oral glucose ingestion at baseline and after 4 weeks of supplementation.
  measure: Blood pressure in the fasted condition
  time frame: 4 weeks
  description: Brachial and aortic blood pressures will be assessed using an automated sphygmomanometry arm cuff (SphygmoCor XCEL). Beat-to-beat blood pressure will be measured using an automated photoplethysmography finger cuff (Fineometer). Blood pressure will be measured at baseline and after 4 weeks of supplementation.
  measure: Blood pressure during acute hyperglycemia
  time frame: 4 weeks
  description: Brachial and aortic blood pressures (systolic and diastolic) will be assessed using an automated sphygmomanometry arm cuff (SphygmoCor XCEL). Beat-to-beat blood pressure will be measured using an automated photoplethysmography finger cuff (Fineometer). Blood pressure will be measured after an oral glucose ingestion at 30, 60, and 90 minutes at baseline and after 4 weeks of supplementation.
  measure: Total peripheral resistance in the fasted condition.
  time frame: 4 weeks
  description: Total peripheral resistance will be measured using an automated photoplethysmography finger cuff (Finometer) at baseline and after 4 weeks of supplementation.
  measure: Total peripheral resistance during acute hyperglycemia
  time frame: 4 weeks
  description: Total peripheral resistance will be measured using an automated photoplethysmography finger cuff (Finometer) at 30, 60, and 90 minutes after oral glucose ingestion at baseline and after 4 weeks of supplementation.
  measure: Stroke volume in the fasted condition
  time frame: 4 weeks
  description: Stroke volume will be measured using an automated photoplethysmography finger cuff (Finometer) at baseline and after 4 weeks of supplementation.
  measure: Stroke volume during acute hyperglycemia
  time frame: 4 weeks
  description: Stroke volume will be measured using an automated photoplethysmography finger cuff (Finometer) at 30, 60, and 90 minutes after oral glucose ingestion at baseline and after 4 weeks of supplementation.
  measure: 24-hour ambulatory blood pressure monitoring
  time frame: 4 weeks
  description: An ambulatory blood pressure cuff, measuring blood pressure for 24-hours will be obtained on two separate days at baseline and after 4 weeks of supplementation.
  measure: Serum glucose and insulin levels.
  time frame: 4 weeks
  description: Serum glucose and insulin levels will be tested at baseline and after 4 weeks of supplementation.
  measure: Serum arginine levels
  time frame: 4 weeks
  description: Serum L-Arginine levels will be tested at baseline and after 4 weeks of supplementation.
  measure: Serum arginase levels
  time frame: 4 weeks
  description: Serum arginase levels will be tested at baseline and after 4 weeks of supplementation.
  measure: Serum Nitric Oxide levels
  time frame: 4 weeks
  description: Serum nitric oxide levels will be tested at baseline and after 4 weeks of supplementation.
  measure: Serum Endothelin-1 levels
  time frame: 4 weeks
  description: Serum endothelin-1 levels will be tested at baseline and after 4 weeks of supplementation.
  arm group label: L-citrulline
  arm group type: Experimental
  description: L-citrulline: 10 grams/day
  arm group label: Placebo
  arm group type: Experimental
  description: Microcrystalline Cellulose
  intervention type: Dietary Supplement
  intervention name: L-Citrulline supplementation
  description: 4 weeks of L-Citrulline supplementation (10 grams/day).
  arm group label: L-citrulline
  intervention type: Dietary Supplement
  intervention name: Placebo
  description: 4 weeks of microcrystalline Cellulose supplementation.
  arm group label: Placebo
  criteria: 
  gender: Female
  minimum age: 45 Years
  maximum age: 79 Years
  healthy volunteers: Accepts Healthy Volunteers
  last name: Arturo Figueroa
  role: Principal Investigator
  affiliation: Texas Tech University
  last name: Arturo Figueroa, Ph.D,MD
  phone: 806-834-5587
  email: arturo.figueroa@ttu.edu
  facility: 
  status: Recruiting
  contact: 
  country: United States
  citation: Figueroa A, Maharaj A, Kang Y, Dillon KN, Martinez MA, Morita M, Nogimura D, Fischer SM. Combined Citrulline and Glutathione Supplementation Improves Endothelial Function and Blood Pressure Reactivity in Postmenopausal Women. Nutrients. 2023 Mar 23;15(7):1557. doi: 10.3390/nu15071557.
  PMID: 37049398
  citation: Maharaj A, Fischer SM, Dillon KN, Kang Y, Martinez MA, Figueroa A. Acute Citrulline Blunts Aortic Systolic Pressure during Exercise and Sympathoactivation in Hypertensive Postmenopausal Women. Med Sci Sports Exerc. 2022 May 1;54(5):761-768. doi: 10.1249/MSS.0000000000002848. Epub 2022 Jan 3.
  PMID: 34974502
  citation: McDonald JD, Mah E, Chitchumroonchokchai C, Dey P, Labyk AN, Villamena FA, Volek JS, Bruno RS. Dairy milk proteins attenuate hyperglycemia-induced impairments in vascular endothelial function in adults with prediabetes by limiting increases in glycemia and oxidative stress that reduce nitric oxide bioavailability. J Nutr Biochem. 2019 Jan;63:165-176. doi: 10.1016/j.jnutbio.2018.09.018. Epub 2018 Sep 25.
  PMID: 30412905
  citation: Figueroa A, Alvarez-Alvarado S, Ormsbee MJ, Madzima TA, Campbell JC, Wong A. Impact of L-citrulline supplementation and whole-body vibration training on arterial stiffness and leg muscle function in obese postmenopausal women with high blood pressure. Exp Gerontol. 2015 Mar;63:35-40. doi: 10.1016/j.exger.2015.01.046. Epub 2015 Jan 28.
  PMID: 25636814
  citation: Maharaj A, Fischer SM, Dillon KN, Kang Y, Martinez MA, Figueroa A. Effects of L-Citrulline Supplementation on Endothelial Function and Blood Pressure in Hypertensive Postmenopausal Women. Nutrients. 2022 Oct 20;14(20):4396. doi: 10.3390/nu14204396.
  PMID: 36297080
  responsible party type: Principal Investigator
  investigator affiliation: Texas Tech University
  investigator full name: Arturo Figueroa
  investigator title: Arturo Figueroa, Principal Investigator
  mesh term: Metabolic Syndrome
  mesh term: Syndrome
  sharing ipd: No